Condition: Solid Tumor, AML Adult · Sponsor: Rubius Therapeutics
Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 monotherapy or in combination of pembrolizumab for the treatment of patients with (1) relapsed/refractory R/R or locally advanced solid tumors (Phase 1/2) or (2) R/R Acute Myeloid Leukemia (AML) (Phase 1 only).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of California San Diego | La Jolla, California, United States | — |
| The Angeles Clinic & Research Institute | Los Angeles, California, United States | — |
| Sarah Cannon Research Institute/ Colorado Blood Cancer Institute | Denver, Colorado, United States | — |
| Sylvester Comprehensive Cancer Center/UMHC | Miami, Florida, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| Columbia University Medical Center | New York, New York, United States | — |
| Oregon Health & Sciences University - Knight Cancer Institute | Portland, Oregon, United States | — |
| Thomas Jefferson University | Philadelphia, Pennsylvania, United States | — |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | — |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | — |
| Virginia Cancer Specialists | Fairfax, Virginia, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04372706